T-cell Acute Lymphoblastic Leukemia Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Nov 2018| TMR1083A| Transparency

Report Highlights

Global T-cell Acute Lymphoblastic Leukemia Market: Overview

This report analyzes the current and future scenario of the global T-cell acute lymphoblastic leukemia market. Increase in patient population with T-cell acute lymphoblastic leukemia, growth of the pharmaceutical industry, improvement in health care infrastructure, and increase in the number of clinical trials are projected to be major drivers of the global market during the forecast period.

The global T-cell acute lymphoblastic leukemia market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on treatment type, end-user, and region. A detailed qualitative analysis of drivers and restraints of the market, and opportunities has been provided in the overview section. Additionally, the section comprises competitive matrix and company profiles along with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis by region and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global T-cell acute lymphoblastic leukemia market.

Global T-cell Acute Lymphoblastic Leukemia Market: Key Segments

Based on treatment, the global T-cell acute lymphoblastic leukemia market has been segmented into chemotherapy, radiation therapy, bone marrow transplant, targeted therapy, and immunotherapy. The segments have been analyzed based on available drug product used during the treatment of T-cell acute lymphoblastic leukemia, cost-effectiveness, and preference for industries. In terms of end-user, the global market has been classified into hospital, clinics, and others. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.

Global T-cell Acute Lymphoblastic Leukemia Market: Regional Outlook

In terms of region, the global T-cell acute lymphoblastic leukemia market has been segmented into North America (U.S. and Canada), Europe (U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, GCC Countries, Israel, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in Report

The report also profiles major players in the global T-cell acute lymphoblastic leukemia market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The major players profiled in the market report include Sanofi, Pfizer, Novartis AG, F. Hoffmann-La Roche Ltd., Erytech Pharma Inc., and Celgene Corporation.

The global T-cell acute lymphoblastic leukemia market has been segmented as below:

Global T-cell Acute Lymphoblastic Leukemia Market, by Treatment
Chemotherapy
Radiation Therapy
Bone Marrow Transplant
Targeted Therapy
Immunotherapy

Global T-cell Acute Lymphoblastic Leukemia Market, by End-user
Hospitals
Clinics
Others

Global T-cell Acute Lymphoblastic Leukemia Market, by Region
North America
U.S.
Canada
Europe
Germany
U.K.
Italy
France
Spain
Rest of Europe
Asia Pacific
India
China
Japan
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Israel
Rest of Middle East & Africa

  • Table 1 : T-cell Acute Lymphoblastic Leukemia Market: Pipeline Analysis
  • Table 2 : Nelarabine: Clinical Trial
  • Table 3 : Authorities Responsible for Reimbursement of Medicines in European Region, 2017
  • Table 4 : Major Regulatory Agencies Responsible for Granting Marketing Authorization for Drugs
  • Table 5 : Global T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) Forecast, by Treatment, 2016–2026
  • Table 6 : Global T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) Forecast, by End-user, 2016–2026
  • Table 7 : Global T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Region, 2016–2026
  • Table 8 : North America T-cell Acute Lymphoblastic Leukemia Market Size Value (US$ Mn) Forecast, by Country, 2016–2026
  • Table 9 : North America T-cell Acute Lymphoblastic Leukemia Market Size Value (US$ Mn) Forecast, by Treatment, 2016–2026
  • Table 10 : North America T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) Forecast, by End-user, 2016–2026
  • Table 11 : Europe T-cell Acute Lymphoblastic Leukemia Market Size Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
  • Table 12 : Europe T-cell Acute Lymphoblastic Leukemia Market Size Value (US$ Mn) Forecast, by Treatment, 2016–2026
  • Table 13 : Europe T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) Forecast, by End-user, 2016–2026
  • Table 14 : Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
  • Table 15 : Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Treatment, 2016–2026
  • Table 16 : Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) Forecast, by End-user, 2016–2026
  • Table 17 : Latin America T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
  • Table 18 : Latin America T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Treatment, 2016–2026
  • Table 19 : Latin America T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by End-user, 2016–2026
  • Table 20 : Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
  • Table 21 : Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Size Value (US$ Mn) Forecast, by Treatment, 2016–2026
  • Table 22 : Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by End-user, 2016–2026
  • Table 23 : Products Offered (Pfizer, Inc.)
  • Table 24 : Products Offered (Novartis AG)
  • Table 25 : Products Offered (F. Hoffmann-La Roche Ltd.)
  • Table 26 : Products Offered (Sanofi)
  • Table 27 : Products Offered (Erytech Pharma, Inc.)
  • Table 28 : Products Offered (Celgene Corporation)
  • Figure 1 : Global T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, 2016–2026
  • Figure 2 : Global T-cell Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2017
  • Figure 3 : Global T-cell Acute Lymphoblastic Leukemia Market Value Share (%), by End-user, 2017
  • Figure 4 : Global T-cell Acute Lymphoblastic Leukemia Market Value Share (%), by Region, 2017
  • Figure 5 : Regulatory Approval Process - U.S.
  • Figure 6 : Regulatory Approval Process - Europe
  • Figure 7 : Regulatory Approval Process - Japan
  • Figure 8 : Global T-cell Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2018 and 2026
  • Figure 9 : Global T-cell Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2018–2026
  • Figure 10 : Global T-cell Acute Lymphoblastic Leukemia Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Chemotherapy, 2016–2026
  • Figure 11 : Global T-cell Acute Lymphoblastic Leukemia Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Radiation Therapy, 2016–2026
  • Figure 12 : Global T-cell Acute Lymphoblastic Leukemia Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Bone Marrow Transplant, 2016–2026
  • Figure 13 : Global T-cell Acute Lymphoblastic Leukemia Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Targeted Therapy, 2016–2026
  • Figure 14 : Global T-cell Acute Lymphoblastic Leukemia Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Immunotherapy, 2016–2026
  • Figure 15 : Global T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2018 and 2026
  • Figure 16 : Global T-cell Acute Lymphoblastic Leukemia Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospitals
  • Figure 17 : Global T-cell Acute Lymphoblastic Leukemia Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Clinics, 2016–2026
  • Figure 18 : Global T-cell Acute Lymphoblastic Leukemia Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2016–2026
  • Figure 19 : Global T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2018–2026
  • Figure 20 : Global T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Region, 2018 and 2026
  • Figure 21 : Global T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Region, 2018–2026
  • Figure 22 : North America T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
  • Figure 23 : North America T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country, 2018 and 2026
  • Figure 24 : North America T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country, 2018–2026
  • Figure 25 : North America T-cell Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2018 and 2026
  • Figure 26 : North America T-cell Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2018–2026
  • Figure 27 : North America T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2018 and 2026
  • Figure 28 : North America T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2018-2026
  • Figure 29 : Europe T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
  • Figure 30 : Europe T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
  • Figure 31 : Europe T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
  • Figure 32 : Europe T-cell Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2018 and 2026
  • Figure 33 : Europe T-cell Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2018–2026
  • Figure 34 : Europe T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2018 and 2026
  • Figure 35 : Europe T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2018-2026
  • Figure 36 : Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
  • Figure 37 : Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
  • Figure 38 : Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
  • Figure 39 : Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2018 and 2026
  • Figure 40 : Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2018–2026
  • Figure 41 : Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2018 and 2026
  • Figure 42 : Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2018-2026
  • Figure 43 : Latin America T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
  • Figure 44 : Latin America T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
  • Figure 45 : Latin America T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
  • Figure 46 : Latin America T-cell Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2018 and 2026
  • Figure 47 : Latin America T-cell Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2018–2026
  • Figure 48 : Latin America T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2018 and 2026
  • Figure 49 : Latin America T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2018-2026
  • Figure 50 : Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, 2016–2026
  • Figure 51 : Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
  • Figure 52 : Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
  • Figure 53 : Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2018 and 2026
  • Figure 54 : Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2018–2026
  • Figure 55 : Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2018 and 2026
  • Figure 56 : Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2018–2026
  • Figure 57 : Global T-cell Acute Lymphoblastic Leukemia Market Share, by Company, 2017
  • Figure 58 : Pfizer, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
  • Figure 59 : Pfizer, Inc. Oncology Business Segment Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2017
  • Figure 60 : Pfizer, Inc. Revenue Share (%), by Business Segment, 2017
  • Figure 61 : Pfizer, Inc. Revenue Share (%), by Region, 2017
  • Figure 62 : Novartis AG Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
  • Figure 63 : Novartis AG Oncology Business Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
  • Figure 64 : Novartis AG Net Sales (%), by Business Segment, 2017
  • Figure 65 : Novartis AG Net Sales (%), by Region, 2017
  • Figure 66 : F. Hoffmann-La Roche Ltd. Oncology Segment Revenue (US$ Bn), 2015–2017
  • Figure 67 : F. Hoffmann-La Roche Ltd. Pharmaceutical Segment R&D Expenditure (US$ Bn), 2015–2017
  • Figure 68 : F. Hoffmann-La Roche Ltd. Pharmaceutical Segment Revenue (%), by Specialty (2017)
  • Figure 69 : F. Hoffmann-La Roche Ltd. Pharmaceutical Segment Revenue (%), by Region (2017)
  • Figure 70 : Sanofi Revenue (US$ Bn), 2014-2017
  • Figure 71 : Sanofi Regional Sales Breakdown (%), 2017
  • Figure 72 : Celgene Corporation Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
  • Figure 73 : Celgene Corporation Marketing & Sales and R&D Expenses (%), 2015–2017
  • Figure 74 : Celgene Corporation Breakdown of Net Sales (%), by Business Segment, 2017
  • Figure 75 : Celgene Corporation Breakdown of Net Sales (%), by Region, 2017

Leaders in analytics, research and advisory services for Fortune 500 companies, scores of high potential startups, and financial institutions. Our success stories have proven why we are a prominent provider of a cutting-edge syndicated and customized research services. Leverage the best of our seasoned research analysts who had a keen interest and enviable expertise of almost 4 million hours in global, regional, and local market intelligence.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
Share This Report